Evidence Explorer · MS-N274 · Supportive physical care · Appraised November 8, 2026
A 108-participant trial reported less neuropathy after five albumin-bound paclitaxel cycles with 23–32 or 34–46 mmHg compression, with the higher-pressure group performing better on some outcomes. The benefit was not present after three cycles, and abstract-level reporting leaves important safety and adherence details unresolved.
Evidence at a glance
- Population: 108 women who developed neuropathy after the first albumin-bound paclitaxel cycle.
- Intervention: grade II (23–32 mmHg) or grade III (34–46 mmHg) compression plus standard care.
- Comparator: standard care alone.
- Key result: no significant incidence difference after three cycles; after five cycles both pressures lowered grade ≥1 neuropathy, and grade III lowered grade ≥2 neuropathy more.
- Evidence label: positive but preliminary single-center, abstract-level evidence.
What was studied
Participants were randomized 1:1:1 and assessed after the third and fifth chemotherapy cycles. Symptom severity and activities-of-daily-living interference also favored compression over time.
Absolute arm-by-arm event counts, analyzed denominators, adherence, adverse events, blinding, prespecified primary outcome and clinically meaningful thresholds were not available in the accessible abstract.
What this evidence cannot establish
This is not evidence that tighter is always better. The trial involved albumin-bound paclitaxel and people with early neuropathy, so it does not establish prevention before symptoms, treatment of chronic CIPN, or equivalence across taxanes and garment types.
Safety and practical context
Higher pressure increases the need for professional fitting and circulation assessment. Pain, pallor, coldness, numbness, skin injury or increasing swelling are stop signals. Peripheral arterial disease, neuropathy, wounds, infection and thrombosis change the risk-benefit balance.
Questions for the care team
- Is this being used for early symptoms or true prevention, and how will neuropathy be graded?
- Has circulation and sensation been assessed before 34–46 mmHg compression?
- What absolute benefit and harm threshold would lead us to continue or stop?
Sources and identifiers
- Randomized trial — PMID 40946043
Funding and conflicts: Only the PubMed abstract and metadata were accessible. Funding, conflicts and complete adverse-event reporting were not verified.
Source access and dates: Original PubMed records and available full texts were checked November 8, 2026. Last literature search November 8, 2026.
Educational evidence summary, not individualized medical advice. Supportive-care outcomes do not demonstrate tumor response, recurrence prevention or longer survival.
